Drilling Down Into the Books for JD.com, Inc. (JD)

JD.com, Inc. (NASDAQ:JD)’s interesting series of developments are underway around the US stock market these days. Now trading with a market value of 60.05B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

JD.com, Inc. (NASDAQ:JD) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For JD, the company currently has 4.91 billion of cash on the books, which is offset by 1.8 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 26.65 billion in total assets, balanced by 19.18 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

JD.com, Inc. (JD) saw 2.26 billion in free cash flow last quarter, representing a quarterly net change in cash of 619.03 million. Perhaps most importantly where cash movements are concerned, the company saw about 2.45 billion in net operating cash flow.

JD.com, Inc. (NASDAQ:JD) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 13.64 billion in total revenues. That represents a quarterly year/year change in revenues of 0.37 in sequential terms, the JD saw sales decline by 0.23.

But what about the bottom line? After all, that’s what really matters in the end. JD.com, Inc. (JD) is intriguing when broken down to its core data. The cost of selling goods last quarter was 11.85 billion, yielding a gross basic income of 1.79 billion. For shareholders, given the total diluted outstanding shares of 1.42 billion, this means overall earnings per share of -0.05. Note, this compares with a consensus analyst forecast of -0.01 in earnings per share for its next fiscal quarterly report.

Is JD.com, Inc. (NASDAQ:JD) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 0.29 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 91.06. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on JD.com, Inc..

Previous ArticleNext Article

Related Post

PDL BioPharma, Inc. (PDLI) vs. Catabasis Pharmaceu... PDL BioPharma, Inc. (NASDAQ:PDLI) shares are up more than 1.82% this year and recently increased 1.09% or $0.03 to settle at $2.79. Catabasis Pharmace...
Medtronic plc (MDT) vs. ResMed Inc. (RMD): Breakin... Medtronic plc (NYSE:MDT) shares are up more than 13.04% this year and recently decreased -0.01% or -$0.01 to settle at $80.52. ResMed Inc. (NYSE:RMD),...
Nxt-ID, Inc. (NXTD) vs. Kratos Defense & Secu... Nxt-ID, Inc. (NASDAQ:NXTD) shares are up more than 84.73% this year and recently increased 15.45% or $0.68 to settle at $5.08. Kratos Defense & Se...
Are Investors Buying or Selling Intelsat S.A. (I),... Recent insider trends for Intelsat S.A. (NYSE:I) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of ...
A Side-by-side Analysis of Opko Health, Inc. (OPK)... Opko Health, Inc. (NASDAQ:OPK) and Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) are the two most active stocks in the Biotechnology industry based on ...